Ibotta CTO sells stock as Definium prepares clinical study results

Ibotta, Inc. CTO Luke Swanson sold 20,100 shares of company stock on September 10th at an average price of $40.04, totaling approximately $804,804. The sale, executed under a pre-arranged Rule 10b5-1 trading plan, represents a 4.31% decrease in his direct ownership. Following the transaction, Swanson retains 446,032 shares valued at roughly $17.86 million.

Separately, Definium Therapeutics announced it will host a live webcast on September 14, 2026, to discuss topline results from Panorama. This is the company’s second Phase 3 study regarding DT120 (lysergide) Orally Disintegrating Tablets for adults suffering from generalized anxiety disorder (GAD).